CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From a closing market price of $103.44 per share on December 19, 2024, Novo's ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

“While the 25% weight loss was not observed in REDEFINE 1, we are encouraged by the weight loss profile of CagriSema, which stands out as one of the most substantial weight reductions observed ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...